Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lucie Valentová Bartáková"'
Autor:
Milan Macek, Pavel Drevinek, Miloslav Marel, Libor Fila, Alzbeta Grandcourtova, Radovan Drnek, Alena Bilkova, Lucie Valentová Bartáková
Publikováno v:
Biomedical Papers, Vol 160, Iss 2, Pp 276-279 (2016)
Aims: Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years togeth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbeddc5d5d03dab2c5efb846599dfe37
https://doi.org/10.5507/bp.2016.029
https://doi.org/10.5507/bp.2016.029
Autor:
Ivana Kurcova, Robert Lischke, Miroslav Zmeškal, Keely Fraser, Eva Králíková, Lucie Valentová Bartáková, Pavel Pafko, Libor Fila
Publikováno v:
Slovenian Journal of Public Health, Vol 55, Iss 1, Pp 29-35 (2016)
Slovenian Journal of Public Health
Slovenian Journal of Public Health
Smoking is associated with a higher incidence of post-lung transplantation complications and mortality. Prior to inclusion on the lung transplant waiting list in the Czech Republic, patients are supposed to be tobacco free for at least 6 months. Our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31fcfba8d47242f5328561329945be49
https://doaj.org/article/d089461de6b84271a6169b164c2128e2
https://doaj.org/article/d089461de6b84271a6169b164c2128e2
Autor:
Libor, Fila, Alžběta, Grandcourtová, Lucie Valentová, Bartáková, Zuzana, Antušová, Eva, Pokojová, Vladimír, Herout, Petr, Jakubec, Radka, Bittenglová, Miloslav, Marel
Publikováno v:
Vnitrni lekarstvi. 62(5)
There is an increasing number of cystic fibrosis (CF) patients with the diagnosis established in adulthood worldwide.To give an overview of our experience with the diagnostics of CF in adulthood in the Czech Republic.CF patients with the diagnosis de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5023f95cbf3905c7b83de392093fa62e
https://pubmed.ncbi.nlm.nih.gov/27319228
https://pubmed.ncbi.nlm.nih.gov/27319228
Autor:
Libor Fila, Lucie Valentova Bartakova, Alzbeta Grandcourtova, Miloslav Marel, Radovan Drnek, Alena Bilkova, Milan Macek, Pavel Drevinek
Publikováno v:
Biomedical Papers, Vol 160, Iss 2, Pp 276-279 (2016)
Aims: Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years togeth
Externí odkaz:
https://doaj.org/article/227fe668bf8c4b7285e574094b698726